Vascon Engineers; Price objective INR 30
Buy in 2 tranches between INR 14.5-12

Strong Execution record: 
The company has strong clientale  and has more than 30 plus years of experience across commercial, residential and own real estate development which include big names

like Cipla SeZ, Ruby Mills  Mumbai, Suzlon  one, MLCP Delhi Airport and various IT companies like Zensar, WNS , IBM, Mastek, Mphasis  etc.

Company has strong order book of 2000 cr which is 4x its FY20 revenue gives visibility of next 2 -3 years. The company has started
winning new orders also.

The company is confident of  reducing its current NET debt of INR 187crores substantially from revenues of existing projects only, Montization of non core assets and sale of Windermere.

The company has taken various cost measures during COVID and
they are likely to remain and would boost profitability of the company and improve margins.

The company has good real estate pipe line of more than 100 cr plus for next 12 -18 months.

75 pc of order book is largely from Government based projects where cash flow issues are
not there.

Company has witnessed good traction in real estate biz post Maharashtra Government announced stamp duty reduction from 5 pc to 2 pc.

Company is confidence of achieving FY20 numbers in FY21 as execution is now at normalcy with sufficient labor availability against
60 pc in Q2. There has been fall in labor wages also in last few weeks.

Most of EPC projects are working in normal fashion now. The company sees maximum impact of 200 cr of slowdown in execution in order book.

The company would sell its non core assets like Mumbai building,
hotel in Goa and land in Aurangabad at right point of time. Proceeds are likely to be used for debt reduction. 

Mid size segment is doing better than affordable and luxury segment. There has been price cuts on luxury segments ( Windermere) by the company but it would help buyer
back to system.

The revenue from MMRCL, Goa  and Police housing to start contributing from Q4 FY21 onwards.

Margins are expected to normalcy in Q3.

The company has inventory of 130 crores in Windermere ( Bungalow require some construction ) and
can generate net cash flow of 65-70 crores for the company .

I believe company can easily do top line of 750 crores with Ebidta of 90-100 crores in FY22.

More from Trading

You May Also Like

1/“What would need to be true for you to….X”

Why is this the most powerful question you can ask when attempting to reach an agreement with another human being or organization?

A thread, co-written by @deanmbrody:


2/ First, “X” could be lots of things. Examples: What would need to be true for you to

- “Feel it's in our best interest for me to be CMO"
- “Feel that we’re in a good place as a company”
- “Feel that we’re on the same page”
- “Feel that we both got what we wanted from this deal

3/ Normally, we aren’t that direct. Example from startup/VC land:

Founders leave VC meetings thinking that every VC will invest, but they rarely do.

Worse over, the founders don’t know what they need to do in order to be fundable.

4/ So why should you ask the magic Q?

To get clarity.

You want to know where you stand, and what it takes to get what you want in a way that also gets them what they want.

It also holds them (mentally) accountable once the thing they need becomes true.

5/ Staying in the context of soliciting investors, the question is “what would need to be true for you to want to invest (or partner with us on this journey, etc)?”

Multiple responses to this question are likely to deliver a positive result.
Moderna CEO Stephane Bancel was previously CEO of bioMerieux in France from 07-10.

Alain Merieux, who owns bioMerieux, was instrumental in the creation of the Wuhan Institute of Virology P4 Lab.

The same people who helped create the virus, also helped to create the vaccines...


Moderna partnered with French Pasteur Institute in 2015 to develop mRNA vaccine technology.

Pasteur Institute partnered with the Wuhan P4 Laboratory in 2017 along with the Merieux Foundation to study emerging viruses...
https://t.co/yFsHwrNYaK
https://t.co/9M5lydBKhM


Nobel prize winning scientist Luc Montagnier asserts that Sars-Cov-2 is man-made and originated from the Wuhan Institute of Virology.

Montagnier did extensive work with the Pasteur Institute in France which was partnered with the Wuhan P4.

Merieux Foundation & the Chinese government have worked together since 1965, and partnered to study emerging pathogens in Africa in 2015.

Their research included "PATHOGENS CARRIED BY BATS" that provoke respiratory diseases.

🚨🚨🚨
https://t.co/gVwpT0ssqI